background phase random placebocontrol observerblind studi ass immunogen reactogen safety inactive splitvirion hn influenza vaccine indonesia child age month year method receive dose day apart contain µg hemagglutinin as adj mg αtocopherol random ratio placebo equal allow age status strain first second vaccine day half remain dose year vaccine value result within status lower limit config inter seroprotect rate thu fulfil unit state european license criterion immune response elicit persist well baseline level reactogen major concern identify concur asbadjuv immunogen show accept profil group studi clinic trial register not 